What Дилатренд Treats: Main Uses and Benefits

Dilatrend (Carvedilol) is commonly used across therapeutic domains where supportive symptom management is appropriate, primarily for chronic cardiovascular conditions involving systemic imbalance. It helps address symptom clusters that create noticeable physiological strain and interfere with functional stability. The medication is commonly used to support patients managing Chronic Heart Failure, Essential Hypertension, and post-acute myocardial infarction stabilization.

Dilatrend is relevant in contexts involving heightened systemic burden, focusing on addressing symptoms related to physical discomfort like fatigue and shortness of breath during activity, and managing persistently high blood pressure readings. The core benefit is providing supportive therapeutic stability and plays a role in managing chronic cardiovascular conditions and may assist with reducing the necessity of hospital stays.

“This support is relevant when symptoms become temporarily overwhelming, offering symptomatic relief that helps patients cope more steadily with challenging cardiac manifestations.”

Quick Fact: Relief for Vascular and Cardiac Strain
Primary Focus	Easing strain associated with heart muscle weakness and high blood pressure.
Symptom Management	Assists with managing symptoms related to physical discomfort (fatigue, dyspnea) and recurrent chronic stable angina.
Overall Benefit	Contributes to maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.

Regulatory References

1. NIH MedlinePlus overview

This section outlines the official eligibility requirements for using Дилатренд (carvedilol), strictly based on governmental regulatory documents.

---

Populations That Must Not Use Дилатренд (Contraindications)

The medicine is formally contraindicated and must not be used by patients who have any of the following conditions, as stated in the official labeling:

• Severe Cardiac Conduction Issues: Patients with second- or third-degree AV block or sick sinus syndrome, unless a permanent pacemaker is in place.
• Severe Bradycardia: Individuals with a heart rate that is too slow, unless a permanent pacemaker is present.
• Acute Heart Failure States: Patients in cardiogenic shock or those with decompensated heart failure who require intravenous medications to support circulation (IV inotropic therapy).
• Respiratory Conditions: Individuals with bronchial asthma or related bronchospastic conditions.
• Organ Dysfunction: Patients diagnosed with severe hepatic (liver) impairment.
• Hypersensitivity: Anyone with a history of a serious hypersensitivity reaction (e.g., Stevens-Johnson syndrome, angioedema) to carvedilol or any component of the formulation.

---

Age and Specific Population Eligibility Status

• Pediatric Use: The safety and effectiveness of Дилатренд have not been established in children and adolescents younger than 18 years of age.
• Pregnancy: The medication is classified under Pregnancy Category C (or equivalent status); it should be used only if the potential benefit justifies the potential risk to the fetus.
• Lactation: It is advised to make a decision to either discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother, as the drug is excreted in breast milk.

---

Patients for whom use is generally allowed are most adults for whom no specific contraindication exists. For patients with non-allergic bronchospasm (e.g., chronic bronchitis), regulatory documents advise avoiding beta-blockers, but use can be considered with caution at the lowest effective dose.

Interaction Map: Interactions with other medicines and products — official regulatory information for Дилатренд (Carvedilol)

Interaction scope Medicinal product categories with documented interactions: CYP P450 Enzyme Modifiers, P-glycoprotein Inhibitors, Hypotensive Agents, Digitalis Glycosides, Diuretics, and Non-Dihydropyridine Calcium Channel Blockers. Specific interacting medicines (if explicitly listed): Rifampin, Cimetidine, Amiodarone, Cyclosporine, and Digoxin. Mechanistic basis of interactions (only if stated in label): Pharmacokinetic (enzyme induction/inhibition, P-glycoprotein inhibition) and Pharmacodynamic (additive effects on heart rate and blood pressure). Timing-based interaction rules (if applicable): Co-administration with food formally slows the rate of absorption. Population-specific interaction notes (if applicable): Severe Hepatic Impairment is a formal restriction; CYP2D6 poor metabolizers exhibit 2- to 3-fold higher plasma concentrations of the R(+)-enantiomer. Interaction-related restrictions: Formal contraindication in patients with severe hepatic impairment.

---

Interaction classifications (high-level)

Interaction severity classification (as defined in official documents): Combinations pose risks categorized as Contraindicated (Severe Hepatic Impairment), Exposure Modification (e.g., Rifampin), or Systemic Risk (e.g., severe bradycardia with Digitalis Glycosides). Regulatory basis (EMA / FDA / etc.): FDA Prescribing Information, NIH DailyMed, and EMA Summary of Product Characteristics. Interaction-context constraints (as defined in official documents): Alcohol may enhance the hypotensive effects; co-administration with food is required in heart failure patients to manage orthostatic symptoms.

---

Resulting interaction structure

Official interaction statements:

• Rifampin significantly reduces carvedilol exposure (AUC/Cmax) by approximately 70% through enzyme induction.
• Carvedilol increases the concentrations of both Cyclosporine and Digoxin; the Cyclosporine increase is formally linked to P-glycoprotein inhibition.
• Co-administration with Digitalis Glycosides or Non-Dihydropyridine Calcium Channel Blockers increases the risk of bradycardia and hemodynamic compromise.
• CYP2D6 inhibitors (e.g., Quinidine, Fluoxetine) are expected to increase the blood levels of the R(+)-enantiomer.
• Hypotensive Agents may increase the risk of severe hypotension and/or bradycardia.

Connection to the overall interaction profile (2–4 sentences): The product’s official interaction profile is structured around identifying both systemic risks and exposure constraints documented by regulatory authorities. This structure emphasizes pharmacodynamic synergy with other agents affecting heart rate and blood pressure, and pharmacokinetic modification by enzyme inducers or inhibitors. Furthermore, the profile defines population-specific risks, such as the high-exposure contraindication for individuals with severe hepatic impairment.

Dual-Action Adrenergic Receptor Blockade

Дилатренд functions as an antagonist (blocker) on three distinct components of the sympathetic nervous system: the beta1 and beta2 adrenergic receptors primarily in the heart, and the alpha1 adrenergic receptors in peripheral vascular smooth muscle. This dual blockade prevents the binding of endogenous signaling molecules (norepinephrine and epinephrine), thereby initiating a central mechanistic cascade. Blockade of the beta receptors induces negative chronotropy (decreased heart rate) and negative inotropy (decreased force of contraction), reducing cardiac workload and oxygen demand. Concurrently, alpha1 blockade inhibits vasoconstrictive signals, promoting the relaxation and widening of arteries (vasodilation).

Systemic and Cellular Modulation

These combined actions result in a reduction in both the heart’s pumping force and the resistance it must overcome, leading to a modulation of systemic vascular resistance (SVR) and arterial pressure. Additionally, Дилатренд exhibits a non-receptor mechanism by acting as an antioxidant. This property influences the process of scavenging free radicals, thereby modulating oxidative stress in cardiovascular tissue. This cellular mechanism influences processes associated with the long-term structural and functional maintenance of the cardiovascular system.

General Administration and Form

The use of Дилатренд (Carvedilol) is based on a structured, gradual protocol for chronic oral administration. The medication must be administered with food to manage the rate of absorption and minimize the incidence of orthostatic effects. Immediate-release tablets are typically taken twice daily, while extended-release capsules are administered once daily. Proper handling requires that extended-release capsules should not be crushed, chewed, or divided.

Dosing Principle and Titration

Dosing is individualized and requires careful, gradual titration. For chronic heart failure, the initial dose for immediate-release tablets is 3.125 mg twice daily. Subsequent dose increases are not to occur until symptoms of worsening heart failure have stabilized, with increases happening at intervals of at least two weeks. This up-titration progresses toward a target dose, which may be up to 50 mg twice daily for patients weighing over 85 kg. For managing hypertension, the starting dose is typically 6.25 mg twice daily, with adjustments made over 7 to 14 day intervals up to a maximum total daily dose of 50 mg. For heart failure, fluid retention must be minimized prior to initiating treatment.

Frequency and Special Use Boundaries

The safety and efficacy of Дилатренд have not been established in the pediatric population, confining its prescribed use to adults. If a dose is missed, it is generally advised to omit the forgotten dose and take the next scheduled dose at the usual time; taking two doses simultaneously is not permitted.

Дилатренд: Recent Clinical Evidence

Дилатренд (active substance: carvedilol) is a non-selective beta-blocker with alpha-1 blocking activity. Research has primarily focused on its use in chronic heart failure (CHF), hypertension, and managing left ventricular dysfunction following a myocardial infarction (heart attack).

---

Key Findings in Chronic Heart Failure (CHF)

Major randomized controlled trials (RCTs) investigating carvedilol in patients with mild to severe CHF (reduced ejection fraction) have consistently indicated a beneficial effect when used in combination with standard therapy (such as ACE inhibitors and diuretics).

• Mortality and Morbidity: Several large-scale studies have shown that the addition of carvedilol to conventional therapy is associated with a statistically significant reduction in all-cause mortality and a lower risk of hospitalization for cardiovascular reasons.
• Cardiac Function: Evidence suggests that carvedilol may contribute to an improvement in left ventricular ejection fraction (LVEF), which is a measure of the heart's pumping efficiency.

---

Comparative Outcomes

One significant trial, the COMET (Carvedilol Or Metoprolol European Trial), directly compared carvedilol with metoprolol tartrate in patients with CHF. This study indicated a reduction in all-cause mortality in the group treated with carvedilol.

Safety Profile and Tolerability

In most clinical trials, carvedilol has been generally well-tolerated. Adverse events were frequently related to its mechanism of action, with common reports including dizziness, fatigue, and a slow heart rate.

Research has shown that, during the initial period of treatment, some patients with heart failure may experience a temporary worsening of symptoms or fluid retention, requiring close clinical monitoring.

Key Studies & References ACC/AHA/HFSA Guideline for the Management of Heart Failure (2022 Guidelines recommending use of carvedilol)

Common questions about Дилатренд (FAQ)

---

Q: Does Дилатренд belong to the group of beta-blockers?

Yes. According to the regulatory documents, Дилатренд (Carvedilol) is classified as a non-selective beta-blocker with vasodilating activity. This means it affects certain heart and vessel receptors, and also causes blood vessels to widen.

---

Q: What is the primary substance (active ingredient) in Дилатренд?

The active substance in Дилатренд is Carvedilol. Official product information confirms that this ingredient is responsible for the medication's therapeutic effects, which include contributing to lower blood pressure and reduced strain on the heart.

---

Q: For what medical conditions is Дилатренд typically prescribed?

Regulatory sources state that Дилатренд is indicated for treating stable chronic heart failure of various origins, arterial hypertension (high blood pressure), and stable angina pectoris (chest pain due to restricted blood flow to the heart).

---

Q: How should I store Дилатренд tablets?

Official information indicates that Дилатренд should be stored in a dry place, protected from light. Regulatory labeling advises keeping the medicine out of the reach of children and checking the expiration date marked on the packaging.

---

Q: Is it safe to suddenly stop taking Дилатренд?

Official information generally advises against suddenly stopping treatment with Дилатренд, particularly for patients with heart failure or coronary artery disease. Abrupt discontinuation may be associated with an exacerbation of the underlying medical condition. The gradual reduction of dosage or discontinuation of the medicine is typically managed by a healthcare professional.

---

Q: Can I drink alcohol while taking Дилатренд?

Studies and official information indicate that alcohol may enhance the effects of Дилатренд, particularly the blood pressure lowering effect. Patients should consult their healthcare provider regarding the use of alcohol, as it may potentiate the blood pressure-lowering effects of Дилатренд.

---

Q: Can Дилатренд be used to treat high blood pressure (hypertension)?

Yes, according to official indications, Дилатренд is approved for the treatment of arterial hypertension. It is used to help lower high blood pressure, which is a key therapeutic goal for this condition.

---

Q: Is Дилатренд suitable for people with asthma?

Regulatory documents state that Дилатренд is contraindicated in patients with bronchial asthma or bronchospasm. This is because the beta-blocking effects of the medicine can potentially cause or worsen breathing difficulties in these specific conditions.

---

Q: What is the recommended timing for taking Дилатренд (e.g., with or without food)?

Regulatory documents indicate that when treating heart failure, Дилатренд is typically administered with food. For hypertension or angina, it may be taken independently of food, but consistent administration related to meals is often used to promote steady absorption.

---

Q: Can Дилатренд be used during pregnancy?

According to the official safety information, the use of Дилатренд is contraindicated during pregnancy due to potential risks to the fetus. Alternative treatment approaches for patients who are pregnant or planning pregnancy are determined by a healthcare provider.

How to Store and Dispose of Дилатренд?

The official storage and disposal requirements for Дилатренд (Carvedilol) are based strictly on regulatory mandates to ensure product stability and safety.

Official Storage Requirements

Condition	Regulatory Requirement
Temperature	Store at Controlled Room Temperature, typically 20°C to 25°C (68°F to 77°F).
Protection	Protect from moisture and light; keep the container tightly closed.
Prohibited	Keep from freezing and away from excessive heat (do not store above 30°C).
Safety	Keep out of the sight and reach of children.

Disposal Instructions

Disposal of unused or expired tablets must be done in accordance with local requirements for pharmaceutical waste. The substance must not be allowed to enter the sewage system or water courses to prevent environmental contamination.